{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:32:58Z","timestamp":1786692778600,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"DOI":"10.1007\/s00784-026-06996-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:12:16Z","timestamp":1783901536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporosis medication exposure patterns and MRONJ occurrence in patients receiving romosozumab: a retrospective observational study"],"prefix":"10.1007","volume":"30","author":[{"given":"Jaeyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiseul","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-1156","authenticated-orcid":false,"given":"Wonse","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"6996_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update. J Oral Maxillofac Surg 80:920\u2013943","journal-title":"J Oral Maxillofac Surg"},{"key":"6996_CR2","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/jcpe.12455","volume":"42","author":"E Gaudin","year":"2015","unstructured":"Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta\u2010analysis. J Clin Periodontol 42:922\u2013932","journal-title":"J Clin Periodontol"},{"key":"6996_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis 24:527\u2013536","journal-title":"Oral Dis"},{"key":"6996_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"6996_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/toxsci\/kfr318","volume":"125","author":"DG Rudmann","year":"2012","unstructured":"Rudmann DG, Page TJ, Vahle JL, Chouinard L, Haile S, Poitout F, Baskin G, Lambert A-J, Walker P, Glazier G (2012) Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci 125:586\u2013594","journal-title":"Toxicol Sci"},{"key":"6996_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metabolism 105:587\u2013594","journal-title":"J Clin Endocrinol Metabolism"},{"key":"6996_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407\u20131416","journal-title":"J Bone Miner Res"},{"key":"6996_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"6996_CR9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double\u2010blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"6996_CR10","doi-asserted-by":"crossref","unstructured":"Lim SY, Bolster MB (2017) Profile of romosozumab and its potential in the management of osteoporosis. Drug design, development and therapy:1221\u20131231","DOI":"10.2147\/DDDT.S127568"},{"key":"6996_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jbmr.3581","volume":"34","author":"D Hadaya","year":"2019","unstructured":"Hadaya D, Gkouveris I, Soundia A, Bezouglaia O, Boyce RW, Stolina M, Dwyer D, Dry SM, Pirih FQ, Aghaloo TL (2019) Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the jaw (ONJ) in rats with experimental periodontitis. J Bone Miner Res 34:171\u2013181","journal-title":"J Bone Miner Res"},{"key":"6996_CR12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"6996_CR13","volume-title":"Evenity (romosozumab): EPAR \u2013 Product Information (Summary of Product Characteristics)","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency (2024) Evenity (romosozumab): EPAR \u2013 Product Information (Summary of Product Characteristics). European Medicines Agency, Amsterdam, The Netherlands"},{"key":"6996_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33:1243\u20131256","journal-title":"Osteoporos Int"},{"key":"6996_CR15","unstructured":"Ministry of Health and Welfare (2020) Partial revision of the Detailed Standards for Reimbursement Application and Methods for Pharmaceuticals [Notice No. 2020\u2009\u2013\u2009271]. Ministry of Health and Welfare, Sejong, Republic of Korea"},{"key":"6996_CR16","volume-title":"EVENITY (romosozumab-aqqg) injection, for subcutaneous use: Prescribing Information","author":"US Food","year":"2019","unstructured":"Food US, Administration D (2019) EVENITY (romosozumab-aqqg) injection, for subcutaneous use: Prescribing Information. U.S. Food and Drug Administration, Silver Spring, MD, USA"},{"key":"6996_CR17","volume-title":"Romosozumab for treating severe osteoporosis (TA791)","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence (2022) Romosozumab for treating severe osteoporosis (TA791). National Institute for Health and Care Excellence, London, United Kingdom"},{"key":"6996_CR18","volume-title":"Final appraisal document \u2013 Romosozumab for treating severe osteoporosis","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence (2022) Final appraisal document \u2013 Romosozumab for treating severe osteoporosis. National Institute for Health and Care Excellence, London, United Kingdom"},{"key":"6996_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00774-024-01530-6","volume":"42","author":"S Soen","year":"2024","unstructured":"Soen S, Wang A, Hamaya E, Chien H-C, Lin T-C (2024) Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019\u20132021. J Bone Miner Metab 42:653\u2013667","journal-title":"J Bone Miner Metab"},{"key":"6996_CR20","doi-asserted-by":"crossref","unstructured":"Lim SY, Bolster MB (2022) Clinical utility of romosozumab in the management of osteoporosis: focus on patient selection and perspectives. Int J Women\u2019s Health :1733\u20131747","DOI":"10.2147\/IJWH.S315184"},{"key":"6996_CR21","doi-asserted-by":"publisher","first-page":"ziaf003","DOI":"10.1093\/jbmrpl\/ziaf003","volume":"9","author":"Y Zhong","year":"2025","unstructured":"Zhong Y, Dai W, Yin L, Wu G, Wang X (2025) Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration Adverse Event Reporting System. JBMR plus 9:ziaf003","journal-title":"JBMR plus"},{"key":"6996_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3803\/EnM.2021.1170","volume":"36","author":"HY Kim","year":"2021","unstructured":"Kim HY (2021) Review and update of the risk factors and prevention of antiresorptive-related osteonecrosis of the jaw. Endocrinol Metabolism 36:917\u2013927","journal-title":"Endocrinol Metabolism"},{"key":"6996_CR23","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","volume":"29","author":"A Srivastava","year":"2021","unstructured":"Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS (2021) Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29:2305\u20132317","journal-title":"Support Care Cancer"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-026-06996-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-026-06996-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-026-06996-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:15:51Z","timestamp":1786691751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00784-026-06996-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6996"],"URL":"https:\/\/doi.org\/10.1007\/s00784-026-06996-4","relation":{},"ISSN":["1436-3771"],"issn-type":[{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosure of potential conflicts of interest\n                      .","order":1,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"317"}}